StopDown
Company

Tata 1mg

Digital healthcare platform

Tata 1mg revenue, valuation and funding

Tata 1mg reported revenue of ₹2,936 crore in FY26 (the year to March 2026), against ₹2,392 crore in FY25, with a net loss of ₹287 crore, per filings and statements as reported.

Tata 1mg revenue, valuation and funding
Revenue (FY26)₹2,936 crore
Revenue (FY25)₹2,392 crore
Revenue (FY24)₹1,968 crore
Net loss (FY26)₹287 crore
Net loss (FY25)₹276 crore
Net loss (FY24)₹313 crore

Figures from filings and statements as reported; the table below carries each year with its source.

Tata 1mg key facts

  • What it doesDigital healthcare platform Story
  • StatusTata Digital unit
₹2,936 croreConsolidated revenueFY26 Profile
₹287 crore lossNet lossFY26 Profile

Tata 1mg revenue and profit by year

Tata 1mg revenue and profit by financial year, ₹ crore, from filings and statements as reported
YearRevenueProfit or lossExpensesNoteSource
FY26₹2,936 crore₹287 crore lossconsolidated, the two Tata 1mg entities combined, as reported by Entrackr from filings; Tata Digital unit, not a standalone company Entrackr
FY25₹2,392 crore₹276 crore loss₹2,682 croreconsolidated, both Tata 1mg entities combined, from Tata Sons' annual report as read by Entrackr; FY25 profit before tax of ₹290 crore in the same article is not reconciled with the loss and is left out EntrackrIndian Startup News
FY24₹1,968 crore₹313 crore loss₹2,303 croreconsolidated, as reported by Entrackr from Tata Sons' annual report Entrackr

As reported for each financial year; where sources disagree the figure is left out rather than picked.

Timeline

  • 2021
  • Jun 2021 Tata Digital acquired a majority stake in 1mg Entrackr
  • 2025
  • Jul 2025 FY25 results: consolidated revenue ₹2,392 crore, loss ₹276 crore Entrackr

The short version

  • Tata 1mg is an online platform selling medicines, supplements and diagnostics; Tata Digital owns it as a group unit. Entrackr
  • Tata Digital took a majority stake in 1mg in June 2021. Entrackr
  • Consolidated FY26 revenue was ₹2,936 crore, up 23 percent from FY25, and the net loss narrowed to ₹287 crore Entrackr
  • Of that, Healthcare Solutions brought ₹2,440 crore and lost ₹310 crore; Technologies brought ₹496 crore and made ₹23 crore profit. Entrackr
  • Rivals named in the report include Netmeds, PharmEasy and Apollo 24/7. Entrackr

Products

  • Medicines and diagnostics: Allopathic, ayurvedic and homeopathic medicines, supplements and lab tests sold online. Entrackr

Questions people ask about Tata 1mg

What is Tata 1mg revenue?

Tata 1mg reported consolidated revenue of ₹2,936 crore in FY26, up 23 percent from FY25. Healthcare Solutions contributed ₹2,440 crore and Technologies ₹496 crore These are the unit's own reported figures; it is part of Tata Digital. Entrackr

Is Tata 1mg profitable?

No. Its net loss in FY26 was ₹287 crore, narrower than before. The Healthcare Solutions entity lost ₹310 crore while the Technologies entity made a ₹23 crore profit. Figures are from Entrackr's reading of filings. Entrackr

What is Tata 1mg valuation?

No valuation figure is reported in the source used here. Tata Digital bought a majority stake in 1mg in June 2021, and the business now runs as a Tata Digital unit, so it has no separate market price. Entrackr

Every line links to the article it came from, written in our own words. Not investment advice. Profile updated 2026-11-14.

Stories cover its results news. Sectors: Healthcare & Life Sciences.

Who put in money

Up against

Reliance-backed NetmedsPharmEasyApollo 24/7

Head to head: PharmEasy vs Tata 1mg →

Every story on Tata 1mg

For Tata 1mg: add the “Featured on StopDown” badge

Put this on your website's press or media page. It links readers to Tata 1mg on StopDown.

Featured on StopDownFeatured on StopDown, dark

· About the badge